Introduction
The PROCARDIS study is a European collaborative project that is using genetic techniques to map susceptibility genes for coronary artery disease (CAD). In the first phase of this research, we have set up a clinical network to recruit families to implement two study designs based on linkage and transmission disequilibrium test (TDT) analyses. We have investigated a haplotype, reported to be associated with myocardial infarction (MI) in Japanese, to test the feasibility of the TDT approach in the late-onset disease CAD.
In a recent large-scale 'genome-wide' association study, 66 000 largely gene-based SNPs were tested for association with MI in a two-stage case -control study that included a total of 1133 Japanese patients. 1 Polymorphisms in the vicinity of the lymphotoxin-a gene (LTA) on chromosome 6p21 showed the strongest evidence of association; haplotype analysis suggested that the association extended in a block over approximately 50 kb and included SNPs within the NFKBIL1 gene (encoding nuclear factor of k light polypeptide gene enhancer in B cells, inhibitor-like 1) and the BAT1 gene (encoding HLA-B-associated transcript 1). The candidature of several SNPs was assessed in in vitro functional studies and highlighted the potential causative role of several of these SNPs as heritable risk factors for myocardial infarction: 252G in intron 1 of LTA was associated with higher transcription and stronger binding of a nuclear factor than 252A; 1 -4 recombinant human N26-LTA induced more VCAM1 and SELE mRNA production from cultured human coronary artery smooth muscle cells than T26-LTA; 1 the À63A allele of the NFKBIL1 promoter, on the same haplotype as LTA 252G and N26, showed slightly lower transcriptional activity. 1 We have tested the postulated association of LTA with CAD in PROCARDIS trio families, who differ from the Japanese in their 'genetic ancestry'. Moreover, the rates of CAD are approximately five-fold lower in Japan than in white European populations such as PROCARDIS, which may in part reflect the different genetic loads present in each population.
Materials and methods
Ascertainment criteria for PROCARDIS probands were MI or symptomatic acute coronary syndrome (SACS; on the assumption that the latter represents a similar pathological process) according to modified WHO diagnostic criteria, 5, 6 before the age of 65 years. Briefly, diagnosis of MI required documentation of two or more of: (a) typical ischaemic chest pain, pulmonary oedema, syncope or shock; (b) development of pathological Q-waves and/or appearance or disappearance of localized ST elevation followed by Twave inversion in two or more standard electrocardiograph leads; (c) increase in concentration of serum enzymes consistent with MI (eg creatine kinase more than twice the upper limit of normal). Diagnosis of SACS required documentation on hospitalization for one of the following indications: (a) unstable angina diagnosed by typical ischemic chest pain at rest associated with reversible ST depression in two or more standard electrocardiograph leads; (b) thrombolysis for suspected MI (as indicated by localized ST elevation in two or more standard electrocardiograph leads) even without later development of Twave inversion, Q-waves or a significant enzyme rise; (c) emergency revascularization (ie during same admission) following presentation with typical ischaemic chest pain at rest.
For the TDT study design, probands completed a questionnaire to establish the availability of their parents and siblings. Both parents whenever possible, or one parent and at least one sibling (affected or unaffected), were then invited to participate, along with any further affected siblings conforming to the PROCARDIS proband definition. Full ethical approval was obtained and all participants gave written informed consent. Families were recruited in four countries: in Sweden and the UK, recruitment was based on existing databases of patients hospitalized for CAD; in Sweden for a few families and in Germany for all, recruitment was through lists of MI patients currently or recently admitted to coronary care units (CCUs); in Italy, recruitment was through both MI patient databases and CCUs.
We extracted DNA from blood using standard techniques. We determined genotype for the lymphotoxin-a T/N26 (804A/C) SNP using the high-throughput PCRbased Sequenom s technology that uses primer extension and detects absolute allele-specific mass differences using MALDI-TOF mass spectrometry. The PCR primers were 5 0 ACGTTGGATGTCAGCACCCCAAGATGCATC3 0 and 5 0 ACGTTGGATGGAGGTCAGGTGGATGTTTAC3' and the extension primer was 5 0 GATGCATCTTGCCCACAGCA3 0 ; an extension/termination mix containing dATP, ddCTP, ddGTP and ddTTP was used.
The programme PedCheck 7 was used to check for misinheritance using the full database of 44 SNPs and three microsatellites genotyped on these families; individuals showing more than two instances of misinheritance were excluded, which in some cases led to the exclusion of entire families. Excess transmission of the LTA N26 allele to the affected offspring was tested using two statistical methods that amalgamate information from complete trios (where genotypes are available for both parents and the proband) and incomplete trios (where genotypes are available from the proband, one parent and one or more additional siblings). First, we used the computer programme Transmit (version 2. 5 8 ) that implements a scoretest function that omits the terms that are most affected by population stratification; the robust variance estimation option was selected to allow for the nonindependence in families with more than one affected sib. We tested for segregation distortion by analysing transmission to offspring not known to be affected, defined as having no selfreported CAD history or symptoms. Secondly, we used the Pedigree Analysis Package (PAP version 5.0, http://hasstedt.genetics.utah.edu), which implements a full-likelihood solution which may not be robust to departures from a panmictic, unstructured population model; 9 maximum likelihood and standard error estimates of genetic parameters were obtained numerically using the GEMINI subroutine.
Results
For this PROCARDIS TDT study, we recruited 460 trio families, comprising 131 with proband and both parents and 329 with proband plus one parent and at least one sibling. PedCheck analysis of all the available genotype data revealed several instances of misinheritance that led to the complete exclusion of 13 families, making a total of 447 families (117 with both parents). LTA with asparagine at amino acid 26 stimulated almost double the production of VCAM1 and E-Selectin mRNAs in cultured human coronary artery smooth muscle cells compared with recombinant LTA with threonine at position 26, and so appears strongly proinflammatory. Using a novel technique to quantitate allele-specific transcriptional activity at any given genomic position, Knight et al 3 were able to show that the LTA 252G-containing haplotype (denoted haplotype A) was more transcriptionally active than another haplotype denoted B, but were unable to distinguish it from a third haplotype C in terms of transcriptional activity. This A or 'active' haplotype corresponds to the A haplotype identified by Ozaki et al, the B haplotype to haplotypes B and C identified by Ozaki et al, and C to D and E, although only haplotype A showed association with MI in the Japanese population-based study. Clearly functional data should be instructive for dissecting the mechanism of action of these SNPs, but obtaining the correct experimental result depends on using the appropriate cell type and stimulus in such in vitro experiments. Therefore, it remains essential to identify disease-causing haplotypes by genetic methods. Our results, together with the Japanese case:control study, suggest that it is the 252G/N26-containing haplotype that is important in vivo in the MI/CAD association. The extent of the LD in this region is known to be high, but Knight et al have shown convincingly that the association with higher transcriptional activity of the LTA 252G allele is not due to LD with the neighbouring TNFa -308G/A SNP, which appears nonfunctional under the conditions tested. LTA association with CAD The PROCARDIS Consortium It remains to be seen whether the LTA 252G/N26 functional haplotype extends further, and whether other individual SNPs in the haplotype are also functional, but the present study strongly reinforces the contention that this haplotype, defined by at least three functional SNPs, may be causally related to MI and/or CAD. A very recent case:control study of MI, also in Japanese, confirmed association of the LTA 10A/252G/N26-containing haplotype with increased risk of MI, although in this study the effect was dominant, with an OR of 1.7 (1.2 -2.3) for presence of the LTA10A allele (10A/252G/N26-haplotype), which is comparable with our genotype risk ratio for the presence of the same haplotype (tagged using the T/N26 SNP) of 1.40 (1.12 -1.77). 12 Both the present study and the Japanese case:control studies were retrospective, therefore, it remains a possibility that the LTA N26 haplotype is a risk factor only in survivors of MI and/or CAD and it would be interesting to investigate this relationship in a prospective setting, perhaps in a nested case:control study.
There has been much discussion recently as to the relative merits of transmission-based tests in trio families versus testing for association in case:control series. Although some investigators have concluded that the problem of population stratification in case:control studies may have been overstated, 13 recent data suggest that it may yet remain a significant problem 14, 15 and so freedom from concerns regarding stratification remains attractive. We note that the Japanese control genotype frequencies for LTA 804C/A were not in Hardy -Weinberg equilibrium, which may have inflated the significance of their findings as some level of admixture may have contributed to this observation. 16 It is also pertinent to note that collection of true negative controls is difficult in CAD as presymptomatic disease will be common in apparently healthy control individuals. In contrast, use of trio families does not require any control population, thus avoiding any such distortion of results. A significant proportion of genotyping errors can be eliminated in trios if they result in Mendelian segregation inconsistencies; 17 this is important as such errors have a negative impact on the power of geneassociation studies. 18 There are concerns that for dominant diseases, excess mortality in the 'carrier' parent will lead to biases. 19 The corollary, however, is that families carrying recessive alleles will be preferentially sampled in trio cohorts and consequently as both parents are informative, the power will be optimal in the TDT design. Additionally, family-based studies uniquely permit parent-of-origin tests. 20 However, overriding all these statistical genetics issues, it is widely believed that it would not be possible to collect sufficient numbers of trio families in a complex, late-onset disease like CAD. 21, 22 By contrast, the present results show that it is possible not only to collect sufficient informative families but also to use them to detect the modest genotype risk ratios expected for such a complex disease. Our success relied on the close coupling of the trio collection with an affected sibling pair collection framework; setting up de novo a project to ascertain and collect trios alone for late-onset diseases would be difficult to justify given prevailing trends.
In conclusion, we have shown strong linkage/association of the LTA haplotype identified by the 804A (N26) allele with CAD, confirming the findings of one of the first genome-wide association studies in a complex trait. As this finding was replicated in a different ethnic group, our data support the likely functional role of the LTA N26 allele in CAD. Finally, we have demonstrated the utility of a complementary experimental design, the trio family approach.
